{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:07:42Z","timestamp":1783976862557,"version":"3.55.0"},"reference-count":98,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sphingosine-1-phosphate (S1P) is a cellular signalling molecule derived from\n                    sphingosine, which is a pro-apoptotic sphingolipid. Sphingolipids control\n                    various cellular actions like growth, homeostasis, and stress-related responses.\n                    The main sources of S1P in our body are erythrocytes. S1P controls both cellular\n                    mediators and other second messengers intracellularly. The S1P receptor also\n                    helps in inflammatory and neuroprotective effects (required to manage of\n                    Parkinson\u02bcs). A large number of anti-Parkinson drugs are available, but still,\n                    there is a need for more effective and safer drugs. S1P and its receptors could\n                    be targeted as novel drugs due to their involvement in neuro-inflammation and\n                    Parkinson\u02bcs. The present review effort to explore the biological role of S1P and\n                    related receptors, for their possible involvement in PD; furthermore. Overall,\n                    S1P and other related metabolizing enzymes have significant therapeutic\n                    opportunities for Parkinson\u02bcs disease along with other neurological\n                    disorders.<\/jats:p>","DOI":"10.1055\/a-2401-4578","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:32:17Z","timestamp":1727825537000},"page":"365-378","source":"Crossref","is-referenced-by-count":1,"title":["Explore the Role of the Sphingosine-1-Phosphate Signalling as a Novel\n                    Promising Therapeutic Target for the Management of Parkinson's\n                    Disease"],"prefix":"10.1055","volume":"74","author":[{"given":"Manoj","family":"Bisht","sequence":"additional","affiliation":[{"name":"Devasthali Vidyapeeth College of Pharmacy, Rudrapur, Uttarakhand,\n                    India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Parkash","family":"Kadian","sequence":"additional","affiliation":[{"name":"Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit\n                    University, Gangoh (Saharanpur)- UP India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuj","family":"Hooda","sequence":"additional","affiliation":[{"name":"MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be\n                    University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Education & Research, Bhagat Phool\n                    Singh Mahila Vishwavidyalaya, Khanpur Kalan, Sonepat, Haryana,\n                    India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Lather","sequence":"additional","affiliation":[{"name":"MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be\n                    University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navidha","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be\n                    University), Mullana-Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.pharep.2018.05.002","article-title":"Sphingosine kinase 1\/sphingosine-1-phosphate receptors dependent signalling in\n                    neurodegenerative diseases. The promising target for neuroprotection in\n                    Parkinson\u02bcs disease","volume":"70","author":"J Motyl","year":"2018","journal-title":"Pharmacological Reports"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u02bcs disease and other dementias: a priority for European\n                    science and society","volume":"15","author":"B Winblad","year":"2016","journal-title":"The Lancet Neurology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/ars.2011.4074","article-title":"Mitochondria and programmed cell death in Parkinson\u02bcs disease: apoptosis and\n                    beyond","volume":"16","author":"C Perier","year":"2012","journal-title":"Antioxidants & Redox Signaling"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/jcm6110100","article-title":"Oxidative stress: mechanistic insights into inherited mitochondrial disorders\n                    and Parkinson\u02bcs disease","volume":"6","author":"M Al Shahrani","year":"2017","journal-title":"Journal of Clinical Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/DDDT.S130514","article-title":"Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in\n                    Alzheimer\u02bcs disease and Parkinson\u02bcs disease","volume":"11","author":"G Ganguly","year":"2017","journal-title":"Drug Design, Development and Therapy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"309302","DOI":"10.1155\/2013\/309302","article-title":"Sphingolipids and brain resident macrophages in neuroinflammation: an emerging\n                    aspect of nervous system pathology","volume":"2013","author":"E Assi","year":"2013","journal-title":"Clinical and Developmental Immunology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10495-015-1101-9","article-title":"The emerging role of Acid Sphingomyelinase in autophagy","volume":"20","author":"C Perrotta","year":"2015","journal-title":"Apoptosis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/cells9061515","article-title":"The S1P\u2013S1PR axis in neurological disorders-Insights into current and future\n                    therapeutic perspectives","volume":"9","author":"A Lucaciu","year":"2020","journal-title":"Cells."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"116071","DOI":"10.1016\/j.biopha.2023.116071","article-title":"The function of sphingolipids in different pathogenesis of Alzheimer\u02bcs disease:\n                    A comprehensive review","volume":"171","author":"X Wang","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tips.2014.03.004","article-title":"Towards selective lysophospholipid GPCR modulators","volume":"35","author":"J K Archbold","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.neuron.2015.01.009","article-title":"Lysophosphatidic acid signaling in the nervous system","volume":"85","author":"Y C Yung","year":"2015","journal-title":"Neuron"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson\u02bcs disease","volume":"403","author":"Y Ben-Shlomo","year":"2024","journal-title":"The Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1094778","DOI":"10.3389\/fnagi.2023.1094778","article-title":"Incidence of Parkinson\u02bcs disease and modifiable risk factors in Korean\n                    population: A longitudinal follow-up study of a nationwide cohort","volume":"15","author":"S H Kang","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"ref14","volume-title":"Parkinson Disease","author":"S Zafar","year":"2023"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ggi.13649","article-title":"Mild cognitive impairment in Parkinson\u02bcs disease: Characterization and impact on\n                    quality of life according to subtype","volume":"19","author":"LF R Vasconcellos","year":"2019","journal-title":"Geriatrics & Gerontology International"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.20471\/may.2023.59.01.24","article-title":"Epidemiology of Parkinson\u02bcs Disease","volume":"59","author":"S Telarovic","year":"2023","journal-title":"Archives of Psychiatry Research"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","article-title":"The impact of non-motor symptoms on the quality of life of Parkinson\u02bcs disease\n                    patients: a longitudinal study","volume":"23","author":"K Prakash","year":"2016","journal-title":"European Journal of Neurology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1590\/0004-282X20160126","article-title":"Unusual motor and non-motor symptoms and signs in the early stage of Parkinson\u02bcs\n                    disease","volume":"74","author":"H A Teive","year":"2016","journal-title":"Arquivos De Neuro-psiquiatria"},{"key":"ref19","first-page":"e33989","article-title":"Quality of Life in Patients With Parkinson\u02bcs Disease: A Cross-Sectional\n                    Study","volume":"15","author":"N Al-Khammash","year":"2023","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson\u02bcs\n                    disease","volume":"32","author":"C Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: a multicenter pooled\n                    analysis","volume":"75","author":"D Aarsland","year":"2010","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","article-title":"The diagnosis of Parkinson\u02bcs disease","volume":"5","author":"E Tolosa","year":"2006","journal-title":"The Lancet Neurology"},{"key":"ref23","first-page":"1","article-title":"The range and nature of non-motor symptoms in drug-naive Parkinson\u02bcs disease\n                    patients: a state-of-the-art systematic review","volume":"1","author":"P Zis","year":"2015","journal-title":"npj Parkinson\u02bcs Disease"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00018-012-1038-x","article-title":"Ceramide function in the brain: when a slight tilt is enough","volume":"70","author":"P Martinez-Martinez","year":"2013","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref25","first-page":"1","article-title":"Distribution and impact on quality of life of the pain modalities assessed by\n                    the King\u02bcs Parkinson\u02bcs disease pain scale","volume":"3","author":"P Martinez-Martin","year":"2017","journal-title":"npj Parkinson\u02bcs Disease"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S1734-1140(11)70665-X","article-title":"Sphingolipid signaling and neuronal function","volume":"63","author":"S I Nakamura","year":"2011","journal-title":"Pharmacological Reports"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s12035-018-1286-3","article-title":"The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling:\n                    Significance for Aging and Neurodegeneration","volume":"56","author":"H Jesko","year":"2019","journal-title":"Mol. Neurobiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"M Maceyka","year":"2014","journal-title":"Nature."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.3390\/ijms25063354","article-title":"Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer","volume":"25","author":"M Nagahashi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","article-title":"Functional roles of sphingolipids in immunity and their implication in\n                    disease","volume":"55","author":"M Lee","year":"2023","journal-title":"Exp Mol Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.3390\/ijms25053024","article-title":"Sphingolipid-Induced Bone Regulation and Its Emerging Role in Dysfunction Due to\n                    Disease and Infection","volume":"25","author":"A Seal","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1288437","DOI":"10.3389\/fncel.2023.1288437","article-title":"The role of sphingosine-1-phosphate in the development and progression of\n                    Parkinson\u02bcs disease","volume":"17","author":"W Wang","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuropharm.2018.02.023","article-title":"Pramipexole And Fingolimod Exert Neuroprotection In A Mouse Model Of Parkinson\u02bcs\n                    disease by activation of sphingosine kinase 1 and Akt kinase","volume":"135","author":"J Motyl","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molcel.2010.10.005","article-title":"Membranes in balance: mechanisms of sphingolipid homeostasis","volume":"40","author":"D K Breslow","year":"2010","journal-title":"Molecular Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/nature08787","article-title":"Orm family proteins mediate sphingolipid homeostasis","volume":"463","author":"D K Breslow","year":"2010","journal-title":"Nature"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"12720","DOI":"10.3390\/ijms241612720","article-title":"Circulating Sphingolipids and Glucose Homeostasis: An Update","volume":"24","author":"S Ali-Berrada","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.phrs.2015.11.006","article-title":"Integrated sphingosine-1 phosphate signaling in the central nervous system: from\n                    physiological equilibrium to pathological damage","volume":"104","author":"R Ghasemi","year":"2016","journal-title":"Pharmacological Research"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1007\/s12035-018-1448-3","article-title":"The role of ceramide and sphingosine-1-phosphate in Alzheimer\u02bcs disease and\n                    other neurodegenerative disorders","volume":"56","author":"K Czubowicz","year":"2019","journal-title":"Molecular Neurobiology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson\u02bcs disease","volume":"125","author":"M Sedelis","year":"2001","journal-title":"Behavioural Brain Research"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12035-013-8622-4","article-title":"Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by\n                    1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells","volume":"50","author":"J Pyszko","journal-title":"Molecular Neurobiology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.neuroscience.2015.01.032","article-title":"Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function\n                    in dopaminergic neurons of mouse model of Parkinson\u02bcs disease and in\n                    MPP+-treated MN9D cells in vitro","volume":"290","author":"M Sivasubramanian","year":"2015","journal-title":"Neuroscience"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3389\/fphar.2019.00807","article-title":"Sphingosine 1-phosphate receptors and metabolic enzymes as druggable targets for\n                    brain diseases","volume":"10","author":"S Grassi","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-024-03221-8","article-title":"The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a\n                    promising therapeutic target","volume":"24","author":"S S Alkafaas","year":"2024","journal-title":"Cancer Cell Int"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1170023","DOI":"10.3389\/fendo.2023.1170023","article-title":"Role of sphingolipid metabolites in the homeostasis of steroid hormones and the\n                    maintenance of testicular functions","volume":"14","author":"D Wang","year":"2023","journal-title":"Front. Endocrinol. Sec. Cellular Endocrinology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnins.2018.00081","article-title":"Silencing of glucocerebrosidase gene in Drosophila enhances the aggregation of\n                    Parkinson\u02bcs disease associated \u03b1-synuclein mutant A53T and affects locomotor\n                    activity","volume":"12","author":"KS B Abul","year":"2018","journal-title":"Frontiers in Neuroscience"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1111\/j.1742-4658.2008.06709.x","article-title":"Emerging pathways in genetic Parkinson\u02bcs disease: potential role of ceramide\n                    metabolism in Lewy body disease","volume":"275","author":"J Bras","year":"2008","journal-title":"The FEBS Journal"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00702-017-1779-7","article-title":"Lysosomal defects in ATP13A2 and GBA associated familial Parkinson\u02bcs\n                    disease","volume":"124","author":"S Sato","year":"2017","journal-title":"Journal of Neural Transmission"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated\n                    Parkinson\u02bcs disease","volume":"37","author":"Y V Taguchi","year":"2017","journal-title":"Journal of Neuroscience"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","article-title":"Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated\n                    Parkinson\u02bcs disease","volume":"636","author":"S Pchelina","year":"2017","journal-title":"Neuroscience Letters"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e73094","DOI":"10.1371\/journal.pone.0073094","article-title":"Plasma ceramide and glucosylceramide metabolism is altered in sporadic\n                    Parkinson\u02bcs disease and associated with cognitive impairment: a pilot study","volume":"8","author":"M M Mielke","year":"2013","journal-title":"PloS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.25729","article-title":"Altered ceramide acyl chain length and ceramide synthase gene expression in\n                    Parkinson\u02bcs disease","volume":"29","author":"S K Abbott","year":"2014","journal-title":"Movement Disorders"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12640-017-9798-6","article-title":"Ceramide and its related neurochemical networks as targets for some brain\n                    disorder therapies","volume":"33","author":"J Brodowicz","year":"2018","journal-title":"Neurotoxicity Research"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2016.09.028","article-title":"Associations between plasma ceramides and cognitive and neuropsychiatric\n                    manifestations in Parkinson\u02bcs disease dementia","volume":"370","author":"Y Xing","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e36475","DOI":"10.1371\/journal.pone.0036475","article-title":"Sphingosine Kinase 1 Deficiency Exacerbates Lps-Induced Neuroinflammation","volume":"7","author":"N M Grinkina","year":"2012","journal-title":"Plos One"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"168000","DOI":"10.1016\/j.jmb.2023.168000","article-title":"Role of Ceramides and Sphingolipids in Parkinson\u02bcs Disease","volume":"435","author":"M Vos","year":"2023","journal-title":"Journal of Molecular Biology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41420-023-01681-x","article-title":"The role of sphingosine-1-phosphate in autophagy and related disorders","volume":"9","author":"S Xiao","year":"2023","journal-title":"Cell Death Discov"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/15548627.2016.1183082","article-title":"Sphk1\/Sphingosine kinase 1-mediated autophagy differs between neurons and\n                    SH-SY5Y neuroblastoma cells","volume":"12","author":"MJ F Manchon","year":"2016","journal-title":"Autophagy"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"492659","DOI":"10.1155\/2015\/492659","article-title":"Exogenous S1P exposure potentiates ischemic stroke damage that is reduced\n                    possibly by inhibiting S1P receptor signaling","volume":"2015","author":"E Moon","year":"2015","journal-title":"Mediators of inflammation"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","article-title":"Sphingosine-1-phosphate receptor therapies: advances in clinical trials for\n                    CNS-related diseases","volume":"113","author":"S O\u02bcsullivan","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.3390\/ijms20215340","article-title":"Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear\n                    Extinction in an MPTP-Induced Mouse Model of Parkinson\u02bcs Disease","volume":"20","author":"T Ishii","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"132931","DOI":"10.1016\/j.neulet.2017.06.050","article-title":"Inflammation And Mitochondrial dysfunction: A vicious circle in\n                    neurodegenerative disorders?","volume":"710","author":"J Van Horssen","year":"2019","journal-title":"Neuroscience Letters"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbi.2015.08.006","article-title":"Transforming growth factor-\u03b21 acts via T\u03b2R-I on microglia to protect against\n                    MPP+-induced dopaminergic neuronal loss","volume":"51","author":"Z Liu","year":"2016","journal-title":"Brain, Behavior, and Immunity"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","article-title":"FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3\n                    Inflammasome Activation","volume":"14","author":"S Yao","year":"2019","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.it.2015.10.005","article-title":"Exit strategies: S1P signaling and T cell migration","volume":"36","author":"A Baeyens","year":"2015","journal-title":"Trends in Immunology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"a020370","DOI":"10.1101\/cshperspect.a020370","article-title":"Astrocytes control synapse formation, function, and elimination","volume":"7","author":"W S Chung","year":"2015","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12325-016-0474-7","article-title":"Modulation of neuroinflammation in the central nervous system: role of\n                    chemokines and sphingolipids","volume":"34","author":"R Gualtierotti","year":"2017","journal-title":"Advances in Therapy"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/scd.2015.0268","article-title":"The adipose mesenchymal stem cell secretome inhibits inflammatory responses of\n                    microglia: evidence for an involvement of sphingosine-1-phosphate\n                    signalling","volume":"25","author":"G Marfia","year":"2016","journal-title":"Stem Cells and Development"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1084\/jem.20181895","article-title":"Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph\n                    nodes","volume":"216","author":"Y Hisano","year":"2019","journal-title":"Journal of Experimental Medicine"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"S J Park","year":"2017","journal-title":"Biomolecules & Therapeutics"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2018.10.029","article-title":"The key role of T cells in Parkinson\u02bcs disease pathogenesis and therapy","volume":"60","author":"J K Baird","year":"2019","journal-title":"Parkinsonism & Related Disorders"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1096\/fj.201600751r","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinson\u02bcs\n                    disease","volume":"31","author":"P Zhao","year":"2017","journal-title":"The FASEB Journal"},{"key":"ref72","first-page":"1","article-title":"Mitochondrial impairment in microglia amplifies NLRP3 inflammasome\n                    proinflammatory signaling in cell culture and animal models of Parkinson\u02bcs\n                    disease","volume":"3","author":"S Sarkar","year":"2017","journal-title":"NPJ Parkinson\u02bcs Disease"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s11481-017-9753-6","article-title":"Fty720 Attenuates Infection-Induced Enhancement Of A\u03b2 Accumulation In App\/Ps1\n                    Mice By Modulating Astrocytic Activation","volume":"12","author":"R M Mcmanus","year":"2017","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","article-title":"FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and\n                    mouse parkinsonian models","volume":"42","author":"M Ren","year":"2017","journal-title":"Neurochemical Research"},{"key":"ref75","first-page":"260","article-title":"The key role of sphingosine kinases in the molecular mechanism of neuronal cell\n                    survival and death in an experimental model of Parkinson\u02bcs disease","volume":"52","author":"J A Pyszko","journal-title":"Folia Neuropathol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.pharep.2015.12.008","article-title":"Regulation of sphingomyelin metabolism","volume":"68","author":"K Bienias","year":"2016","journal-title":"Pharmacological Reports"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1074\/jbc.RA118.001986","article-title":"Extracellular \u03b1-synuclein drives sphingosine 1-phosphate receptor subtype 1 out\n                    of lipid rafts, leading to impaired inhibitory G-protein signaling","volume":"293","author":"SM M Badawy","year":"2018","journal-title":"Journal of Biological Chemistry"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"20811","DOI":"10.1074\/jbc.M116.744029","article-title":"FTY720\/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice\n                    Contributions Of Pro-Brain-Derived Neurotrophic Factor (Pro-Bdnf) And Mature\n                    BDNF","volume":"291","author":"G Vidal-Mart\u00ednez","year":"2016","journal-title":"Journal of Biological Chemistry"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.14336\/AD.2017.0717","article-title":"BDNF polymorphism: a review of its diagnostic and clinical relevance in\n                    neurodegenerative disorders","volume":"9","author":"T Shen","year":"2018","journal-title":"Aging and Disease"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fphar.2020.00077","article-title":"Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation\n                    and Prevent Parkinson\u02bcs Disease Symptoms in the 1-Methyl-4-Phenyl-1, 2, 3,\n                    6-Tetrahydropyridine Mouse Model","volume":"11","author":"E Pepin","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.001","article-title":"Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent\n                    advances","volume":"62","author":"S Pyne","year":"2016","journal-title":"Progress in Lipid Research"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","article-title":"The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic\n                    agent: Recent findings and new perspectives","volume":"185","author":"A Huwiler","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"24939","DOI":"10.1038\/srep24939","article-title":"Fingolimod modulates multiple neuroinflammatory markers in a mouse model of\n                    Alzheimer\u02bcs disease","volume":"6","author":"N Aytan","year":"2016","journal-title":"Scientific Reports"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.brainres.2015.07.055","article-title":"Glun2b-containing NMDA Receptors Are Upregulated in Plasma Membranes by the\n                    Sphingosine-1-Phosphate analog FTY720P","volume":"1624","author":"S A Essis","year":"2015","journal-title":"Brain Research"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond\n                    Multiple Sclerosis","volume":"81","author":"T P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-017-1788-5","article-title":"Parkinson\u02bcs disease: experimental models and reality","volume":"135","author":"P Jiang","year":"2018","journal-title":"Acta Neuropathol"},{"key":"ref87","first-page":"17590914","article-title":"Neurotoxin-induced animal models of Parkinson disease: pathogenic mechanism and\n                    assessment","volume":"10","author":"X S Zeng","year":"2018","journal-title":"ASN Neuro"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u02bcs disease: clinical features and diagnosis","volume":"79","author":"J Jankovic","year":"2019","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"ref89","first-page":"w13293","article-title":"Parkinsonism: heterogeneity of a common neurological syndrome","volume":"141","author":"G Kaegi","year":"2011","journal-title":"Swiss Medical Weekly"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT)\n                    with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"N Bajaj","year":"2013","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00702-017-1717-8","article-title":"Magnetic resonance imaging for the diagnosis of Parkinson\u02bcs disease","volume":"124","author":"B Heim","year":"2017","journal-title":"Journal of Neural Transmission"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u02bcs disease","volume":"30","author":"R B Postuma","year":"2015","journal-title":"Movement Disorders"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"634490","DOI":"10.3389\/fneur.2020.634490","article-title":"Prodromal Parkinson\u02bcs Disease","volume":"11","author":"D Crosiers","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11910-017-0738-x","article-title":"Subtypes of Parkinson\u02bcs disease: what do they tell us about disease\n                    progression?","volume":"17","author":"S M Fereshtehnejad","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/14728222.12.4.425","article-title":"Potential therapeutic targets for Parkinson\u02bcs disease","volume":"12","author":"J Stoessl","year":"2008","journal-title":"Expert opinion on therapeutic Targets"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/bs.irn.2017.03.004","article-title":"New symptomatic treatments for the management of motor and nonmotor symptoms of\n                    Parkinson\u02bcs disease","volume":"132","author":"R N Taddei","year":"2017","journal-title":"International Review of Neurobiology"},{"key":"ref98","first-page":"217","article-title":"Early (uncomplicated) Parkinson\u02bcs disease","volume":"1","author":"W Oertel","year":"2011","journal-title":"European handbook of Neurological Management"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy\n                    models","volume":"114","author":"S P Sardi","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2401-4578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:42:57Z","timestamp":1730806977000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2401-4578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":98,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2401-4578","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}